Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a biotech company with a promising outlook, as their proprietary synthetic psilocybin formulation, COMP360, has Breakthrough Therapy designation from the US FDA and has received Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression (TRD). With positive results from phase 2 and 3 clinical trials for TRD and ongoing trials for other mental health disorders, Compass Pathways is well-positioned to become a leader in the emerging field of psychedelic therapies. The company has a strong research bench and a global network of treatment centers, indicating potential for significant future growth.

Bears say

Compass Pathways is facing numerous risks, including clinical, regulatory, and commercial risks, as well as the possibility of dilutive equity offering. Even though their current valuation is approximately $9.6 billion with a price target of $70, there are significant risks to achieving this target, such as clinical development risk, competitor risk, and government regulatory risk. The recent news of a suspected completed suicide in one of their trials also brings up concerns about the safety and efficacy of their treatment. Overall, there are significant uncertainties surrounding Compass Pathways, making it a risky investment.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Jul 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.